- BrainStorm Cell Therapeutics (BCLI -5.0%) partners with Rapid Reshore & Development (RR&D) to expedite site selection and design services for a manufacturing facility for NurOwn in the U.S.
- The ~50K-square foot building will contain manufacturing suites, and the ability to expand the facility to 100K square feet to anticipate future needs.
- NurOwn technology platform is used to produce autologous MSC-NTF cells, which have received Orphan Drug status in the U.S. and Europe for the treatment of amyotrophic lateral sclerosis (ALS).
-
Phase 3 trial in ALS is fully enrolled, and is investigating repeat administration of autologous MSC-NTF cells. Recently, the company completed enrollment in Phase 2 trial in progressive multiple sclerosis.